Zymeworks Inc. (NASDAQ: ZYME) closed a $250 million non‑recourse royalty‑backed note with Royalty Pharma plc on March 2, 2026. The note is secured by 30 % of worldwide tiered royalties on sales of Ziihera (zanidatamab‑hrii), the company’s first approved bispecific antibody, under its collaboration agreements with Jazz Pharmaceuticals and BeOne Medicines. Royalty Pharma will receive repayments from the royalty stream until it has collected either 1.65 × the note amount by December 31, 2033, or 1.925 × the note amount at any time thereafter. Zymeworks will retain 70 % of Ziihera royalties during the repayment period, with full royalty rights reverting to the company once the note is fully repaid.
The $250 million infusion provides Zymeworks with non‑dilutive capital that can be deployed for share repurchases, strategic acquisitions, and ongoing operations, extending the company’s cash runway beyond 2028. Management emphasized that the financing “provides non‑dilutive capital that enhances flexibility for share repurchases, strategic acquisitions, and funding operations well into the next decade,” underscoring the company’s confidence in its royalty‑driven business model and the commercial potential of Ziihera in HER2‑positive biliary tract and gastro‑esophageal cancers.
On the same day, Zymeworks reported Q4 2025 earnings that fell short of expectations. Revenue declined to $2.5 million from $31.0 million in Q4 2024, and the company posted a net loss of $41.2 million versus a $23.5 million loss in the prior year. Earnings per share were $-0.55, missing the consensus estimate of $-0.35. The revenue miss reflects a sharp drop in sales volume, while the widened loss is driven by higher operating expenses and one‑time charges associated with product development and regulatory activities.
The earnings miss highlights headwinds in the company’s early‑stage pipeline and the limited commercial traction of its current assets. Management noted that the Q4 loss was “largely attributable to increased R&D and regulatory costs as the company advances its pipeline and prepares for future commercial launches.” The decline in revenue also signals a temporary slowdown in the market for bispecific antibodies, which may be influenced by competitive dynamics and pricing pressures in the oncology space.
Full‑year 2025 results show a more positive trajectory: revenue rose to $106.0 million, up from $76.3 million in 2024, driven by milestone payments and early sales of Ziihera. However, the company’s net loss widened to $81.1 million from $122.7 million in 2024, reflecting continued investment in research and development. Management reiterated its confidence in the long‑term value of Ziihera, stating that “the topline results from HERIZON‑GEA‑01 represent a true turning point for patients with HER2‑positive gastroesophageal adenocarcinoma, marking real progress in an indication that has historically had limited treatment options and poor outcomes.”
Zymeworks’ dual focus on securing non‑dilutive capital and reporting earnings that underscore both challenges and growth opportunities positions the company to navigate short‑term headwinds while pursuing its long‑term strategy of building a royalty‑driven biopharmaceutical portfolio. The financing strengthens its balance sheet, while the earnings data provide a realistic view of the company’s current operational performance and the need for continued investment in its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.